Growth factors such as glial cell line-derived neurotrophic factor (GDNF) were initially thought to be exciting new treatments for Parkinson’s disease (PD), but trials have been disappointing. A panel of prominent leaders in the field convened to discuss whether there is a future for this approach and what any future PD trial involving GDNF and other GDNF family neurotrophic factors should consider. Their discussions and recommendations are published in the Journal of Parkinson’s Disease.
- Oncotarget: Evaluation of cellular alteration & inflammatory profile of cells
- Cause of Alzheimer’s disease traced to mutation in common enzyme
- Elkhorn coral actively fighting off diseases on reef, study finds
- Mary Ann Liebert, Inc. to publish Journal of Correctional Health Care
- Exploring the source of stars and planets in a laboratory